+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

ASA Travel Award

Australian Society for Antimicrobials

ASA has made funds available for travel awards to assist Members wanting to attend the Society’s Annual Scientific Meeting.

Awards are presented to ASA financial members who present a proffered paper (oral or poster) at the meeting.
Applicants must have current ASA membership and must have been ASA members for at least the last 12 months.
Recipients of an Award are required to write a report on the meeting for the ASA Newsletter.

The awards consist of return economy airfare, accommodation, and meeting registration for Antimicrobials 2026, valued at up to AUD 2,500.

ASA members who wish to apply for this award are invited to submit their application to the ASA Secretary at info@asainc.net.au by Friday 12th December 2025. The application should include a copy of the abstract, and for abstracts with more than one author, a letter stating the relative contribution of the applicant towards the research.

AI Based Application Success Predictor

✅ 1. Clear antimicrobial resistance (AMR) relevance

Highest-scoring proposals explicitly target AMR problems—NOT general microbiology.

Strong alignment examples:

Mechanisms of resistance (β-lactamases, carbapenemases, mcr genes)

Novel antimicrobial compounds or adjuvants

Resistance transmission in clinical/hospital settings

Biofilm persistence

Indirect infection biology without resistance relevance underperforms.

✅ 2. Clinical stewardship impact

ASA strongly rewards:

Intervention studies reducing inappropriate prescribing

Optimization of antimicrobial dosing

Hospital stewardship audits

Decision-support tools

Linking stewardship + measurable outcomes is a recurring success signal.

✅ 3. Translational potential matters

Winning proposals often show a path from mechanism → clinical utility:

Diagnostic parameter that affects prescribing decision

Surveillance system that updates guidelines

Compound that advances toward preclinical validation

“Interesting but unimplementable” → weakens enthusiasm.

✅ 4. Strong preliminary feasibility

Panels reliably favor applicants who demonstrate:

Pilot resistance phenotyping assays

Compound activity data (MIC values, kill curves)

Access to resistant isolates

Biofilm screens

A complete reliance on future data → reviewer skepticism.

✅ 5. Robust antimicrobial methodology

Recurring experimental preferences:

MIC/MBC with standards (EUCAST/CLSI)

Time–kill assays

Checkerboard synergy

Resistance development/passaging

PK/PD modeling

Proposals missing standardized methods receive methodological concerns.

✅ 6. Access to clinical isolates

Winning investigators often partner with:

hospital microbiology labs,

state reference labs,

wastewater environmental surveillance groups.

Demonstrated sample access significantly boosts feasibility.

✅ 7. Novel target or mechanism

Reviewers are increasingly drawn to:

cell envelope synthesis pathways,

efflux pump modulation,

metabolic vulnerabilities,

virulence factor inhibition.

Generic broad-spectrum claims without rationale fare poorly.

✅ 8. One-Health framing

ASA has become receptive to proposals that integrate:

veterinary antibiotic use,

environmental contamination,

agricultural microbiome impact.

Showing cross-sector transmission increases fundability.

✅ 9. Bioinformatic support

Patterns in awarded proposals include:

resistome profiling,

genome-wide association analyses,

phylogenomic outbreak tracing.

A collaborator bioinformatician is a repeat predictor of success.

✅ 10. Feasible sample size & statistics

Reviewers consistently critique:

underpowered clinical audits,

unclear endpoints,

missing analytic plans.

Even simple power logic helps.

✅ 11. Clear plan for dissemination

Winning proposals often highlight:

integration with hospital stewardship committees,

policy brief generation,

incorporation into national guidelines (Antibiotic Reference Groups Australia).

🧫 Scientific Themes Common in Past Winners

Carbapenem resistance mechanisms

ESBL transmission

mcr-mediated colistin resistance

MRSA/MSSA comparative genomics

Biofilm disruption strategies

Diagnostic stewardship

🔍 For early-career applicants

Highly predictive factors:

Departmental mentor with AMR publications

Co-authored stewardship study

Presentations at ASA Annual Meeting

Demonstrated emergence of independence (first/last authorship)

Generic letters of support hurt competitiveness.

📉 Common Reviewer Critiques

Patterns repeatedly observed:

✘ “Scope not achievable within funding duration”
✘ “FTD-style mechanistic work without AMR relevance”
✘ “Preliminary data insufficient to support proposed assays”
✘ “Diagnostic readout lacks clinical adoption path”
✘ “Environmental sampling poorly powered”

🧠 Ideal Aim Structure

Successful shapes often look like:

Aim 1 — Define resistance mechanism or target vulnerability
Aim 2 — Validate inhibition or stewardship intervention in clinically relevant isolates
Aim 3 — Model translational impact (PK/PD, prescribing outcomes, uptake pathway)

Two solid aims > three weak.

💰 Budget Predictors

High performers:

reagent-heavy consumables budget

sequencing via institutional core

minimal equipment purchase

clear stewardship/travel justification

Weak budgets:

disproportionate personnel funding

equipment without core justification

🏁 Summary: Strongest Predictors

A competitive ASA proposal typically includes:

✅ explicit antimicrobial resistance relevance
✅ preliminary feasibility data (MICs, isolates, pilot stewardship metrics)
✅ clinical or environmental isolate access
✅ standardized antimicrobial methods
✅ translational clinical benefit or stewardship improvement
✅ bioinformatic and statistical support
✅ feasible scope within small grant budgets
✅ clear dissemination to clinics or policy

Specialties

Microbiology

Eligibility Requirements

Awards are presented to ASA financial members who present a proffered paper (oral or poster) at the meeting.
Applicants must have current ASA membership and must have been ASA members for at least the last 12 months.
Recipients of an Award are required to write a report on the meeting for the ASA Newsletter.

Eligible Countries:

Australia

New Zealand

Sponsor Details

Sponsor Institute/Organizations: Australian Society for Antimicrobials

Sponsor Type: Corporate/Non-Profit

Address: P.O. Box 6705 East Perth 6892 Western Australia

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity